名創優品(09896.HK)迴應Blue Orca Capital沽空報告:該報告毫無依據 且包含誤導性結論及詮釋
格隆匯7月27日丨名創優品(09896.HK)今日發佈,以回覆沽空機構Blue Orca Capital於一份沽空機構報告中的指控。公司認爲,該報告毫無依據,且包含有關公司資料的誤導性結論及詮釋。
董事會(包括審計委員會)正在審查該等指控,並考慮採取適當行動以保護所有股東的利益。基於公司管理層的建議併爲保護所有股東的利益,董事會決定成立由獨立董事徐黎黎、朱擁華及王永平所組成的獨立委員會,旨在監督就該報告中相關指控所開展的獨立調查工作。獨立委員會得於適當時聘請獨立專業顧問協助獨立調查。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.